Clinical Trials Directory

Trials / Completed

CompletedNCT00658346

Molecular Diversity of HIV-1 Group O Strains and Treatment Management in Cameroon

Status
Completed
Phase
Study type
Observational
Enrollment
141 (actual)
Sponsor
ANRS, Emerging Infectious Diseases · Other Government
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Infections with HIV-1 group O are found in 1 to 3 % of persons living with HIV in Cameroon. The natural history and treatment response is not well understood. The natural resistance to non nucleoside reverse transcriptase inhibitors and their possible low sensitivity to protease inhibitors complicate the choice of an adequate treatment options. This observational study is aimed at evaluating the antiretroviral treatment response of HIV-1 group O infected patients in comparison with HIV-1 group M infected patients. The proposed standardized follow-up will facilitate a better understanding of the natural history and treatment specificities to improve the patients management. This is a non randomized study, open label, with standardized follow-up. A total of 171 patients

Conditions

Interventions

TypeNameDescription
DRUGTreatment initiation for HIV-1 group O infected patientsThe first line regimen is adapted according to the hemoglobin level and the AgHBs status : * If Hb \> 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA) * If Hb \<= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA) * If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA)
DRUGTreatment initiation for HIV-1 group M infected patientsThe first line regimen is adapted according to the hemoglobin level and the AgHBs status : * If Hb \> 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA) * If Hb \<= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA) * If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA)

Timeline

Start date
2010-06-01
Primary completion
2015-08-01
Completion
2016-09-01
First posted
2008-04-15
Last updated
2017-01-12

Locations

2 sites across 1 country: Cameroon

Source: ClinicalTrials.gov record NCT00658346. Inclusion in this directory is not an endorsement.